Marguerite Parisi, M.D., MS Ed.

Professor
Pediatric Radiology

Recent Publications

See all publications on Scopus

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children’s Oncology Group phase II study
Shusterman S., Naranjo A., van Ryn C., Hank J., Parisi M., Shulkin B., Servaes S., London W., Shimada H., Gan J., Gillies S., Maris J., Park J., Sondel P.
Clinical Cancer Research. 2019 Oct:6044-6051

Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach
Parisi M., Khalatbari H., Parikh S., Alazraki A.
Pediatric Radiology. 2019 Oct:1391-1403

Utility of 18F-FDG PET/CT in Infantile Myofibromatosis
Tang E., Khalatbari H., Parisi M.
Clinical Nuclear Medicine. 2019 Aug:676-679

Update: Image Gently and Nuclear Medicine at 10 Years
Treves S., Gelfand M., Parisi M., Lassmann M., Goske M., Sexton-Stallone B., Fahey F.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Apr:7N-9N

Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin
McNeil M., Parisi M., Hijiya N., Meshinchi S., Cooper T., Tarlock K.
Journal of pediatric hematology/oncology. 2019 Apr:e174-e176

Radioisotope Therapies: Iodine-131, I-131-MIBG, and Beyond
Kwatra N., Parisi M., Shulkin B.
Pediatric Oncology. 2019 Jan:275-303

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study
Braunstein S., London W., Kreissman S., Villablanca J., Davidoff A., DeSantes K., Castleberry R., Murray K., Diller L., Matthay K., Cohn S., Shulkin B., von Allmen D., Parisi M., Van Ryn C., Park J., La Quaglia M., Haas-Kogan D.
Pediatric Blood and Cancer. 2019 Jan

Part-time pediatric radiology: The realities and perceptions of part-time employment in the academic setting
Menashe S., Parisi M., Chapman T., Stanescu A., Wright J., Otto R., Iyer R.
American Journal of Roentgenology. 2018 Nov:971-977

Corrigendum: A comprehensive safety trial of chimeric antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children’s Oncology group study ANBL0931 [Front Immunol, 9, 1355, (2018)] DOI: 10.3389/fimmu.2018.01355
Ozkaynak M., Gilman A., London W., Naranjo A., Diccianni M., Tenney S., Smith M., Messer K., Seeger R., Patrick Reynolds C., Smith L., Shulkin B., Parisi M., Maris J., Park J., Sondel P., Yu A.
Frontiers in Immunology. 2018 Jul

A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children’s oncology group study ANBL0931
Ozkaynak M., Gilman A., London W., Naranjo A., Diccianni M., Tenney S., Smith M., Messer K., Seeger R., Reynolds C., Smith L., Shulkin B., Parisi M., Maris J., Park J., Sondel P., Yu A.
Frontiers in Immunology. 2018 Jun